BG Medicine (BGMD) Reports Galectin-3 Might Be Independent Predictor of Adverse Outcomes in ESRD Patients

BG Medicine, Inc. (Nasdaq: BGMD), announced today that results from a study on the role of galectin-3 in patients with end-stage renal disease (ESRD) were presented at the American Heart Association's Scientific Sessions 2011 (AHA) meeting in Orlando, Florida on November 16, 2011. Results from this study suggest that galectin-3 may be an independent predictor of adverse outcomes in patients with ESRD, due to the association of galectin-3 with all-cause and infectious mortality, stroke and other cardiovascular events.

The study included 1,168 patients with diabetes undergoing dialysis who participated in the German Diabetes and Dialysis Study. Galectin-3 was measured in baseline blood samples, with a median follow up period of 4 years, during which 617 patients (49%) died. Regression analysis was used to assess the association of galectin-3 with the development of all-cause mortality, sudden cardiac death, death due to heart failure, death due to infection, cardiovascular events, myocardial infarction and stroke.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Gray Media closes $750M note offering to refinance higher-rate debt
• Cytek faces $56M damages award in Beckman Coulter patent case